Vascular endothelial growth factors and methods of their use

Details Vascular endothelial growth factors and methods of their use Vascular endothelial growth factors and methods of their use

2005-01-27

2011-11-29

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S399000, C606S228000, C606S231000

Reexamination Certificate

active

08067368

ABSTRACT:
Vascular endothelial growth factor alternative splice variants and methods of their use are provided.

REFERENCES:
patent: 4373217 (1983-02-01), Draenert
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 6140073 (2000-10-01), Bayne et al.
patent: 2003/0114366 (2003-06-01), Martin et al.
patent: 2005072417 (2005-08-01), None
Claffey, et al. “Vascular Endothelial Growth Factor”, The Journal of Biological Chemistry (1992), vol. 267, No. 23, pp. 16317-16322.
Cui, et al. “Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein”, Am. J. Physiol Renal Physiol. (2004), vol. 286, No. 4, pp. F767-F773.
Ferrara, “Vascular Endothelial Growth Factor”, European J. of Cancer (1996), vol. 52A, No. 14, pp. 2413-2422.
Grunstein, et al. “Isoforms of Vascular Endothelial Growth Factor Act in a Coordinate Fashion to Recruit and Expand Tumor Vasculature”, Molecular and Cellular Biology (2000), vol. 20, No. 19, pp. 7282-7291.
Hopp, et al. “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification”, Bio/Technology (1988), vol. 6, pp. 1204-1210.
Ito, et al. “Hair follicle stem cells in the lower bulge form the secondary germ, a biochemically distinct but functionally equivalent progenitor cell population, at the termination of catagen”, Differentiation (2004), vol. 72, pp. 548-557.
Larrick, et al. “Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes from Single Hybridoma Cells”, Bio/Technology (1989), vol. 7, p. 934-938.
Liu, et al. “Chimeric Mouse-Human IgG1 Antibody that Can Mediate Lysis of Cancer Cells Chimeric Mouse-Human IgG1 Antibody that Can Mediate Lysis of Cancer Cells”, PNAS (1987), vol. 84, pp. 3439-3443.
Maniatis, et al. “Molecular Cloning (A Laboratory Manual)”, Cold Spring Harbor Laboratory (1982), pp. 387-389.
Mihm, et al. “Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase”, Br. J. Pharmacol. (2002), vol. 135, No. 3, pp. 581-588.
Needleman, et al. “A general method applicable to the search for similarities in the amino acid sequence of two proteins”, J. Mol. Bio. (1970), vol. 48, pp. 443-453.
International Search Report for WO 2005/072417 (PCT/US2005/002929), mailed Feb. 4, 2009.
Written Opinion for WO 2005/072417 (PCT/US2005/002929), mailed Feb. 20, 2009.
International Preliminary Report on Patentability for WO 2005/072417 (PCT/US2005/002929), mailed Feb. 24, 2009.
Affara, et al. “Vascular Endothelial Growth Factor as a Survival Factor in Tumor-Associated Angiogenesis”, in vivo, (2004), vol. 18, pp. 525-542.
Bates, et al. “VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Is Down-Regulated in Renal Cell Carcinoma”, Cancer Research, (2002), vol. 62, No. 14, pp. 4123-4131.
Bates, et al. “VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant Mechanism of Action, In vivo Effect on Angiogenesis and Endogenous Protein Expression”, Cancer Research (2004), vol. 64, No. 21, pp. 7822-7835.
Borgstrom, et al. “Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin”, Anticancer Research (1999), vol. 19, No. 5B, pp. 4203-4214.
Ortiz, et al. “Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects”, PNAS (2003), vol. 100, No. 14, pp. 8407-8411.
Ozerdem, et al “Early Contribution of Pericytes to Angiogenic Sprouting and Tube Formation”, Angiogenesis (2003), vol. 6, No. 3, pp. 241-249.
Riechmann, et al. “Reshaping human antibodies for therapy”, Nature (1988), vol. 332, pp. 323-327.
Robertson, et al. “Gene expression and cellular sources of inducible nitric oxide synthase during tumor promotion”, Carcinogenesis (1996), vol. 17, No. 9, pp. 2053-2059.
Robinson, et al. “The splice variants of vascular endothelial growth factor (VEGF) and their receptors”, J. of Cell Science (2001), vol. 114, No. 5, pp. 853-865.
Song, et al. “Angiogenic role for glycodelin in tumorigensis”, PNAS (2001), vol. 96, No. 16, pp. 9265-9270.
Sugihara, et al. “A Novel Alternatively Spliced Form of murine Vascular Endothelial Growth Factor, VEGF 115*”, The Journal of Biological Chemistry (1998), vol. 273, No. 5, pp. 3033-3038.
Tober, et al. “Comparative Expression of Novel Vascular Endothelial Growth FactorNascular Permeability Factor Transcripts in Skin, Papillomas, and Carcinomas of v-Ha-ras Tg.AC Transgenic Mice and FVB/N Mice”, Biochemical and Biophysical Research Communications (1998), vol. 247, pp. 644-653.
Trempus, et al. “Enrichment for Living Murine Keratinocytes from the Hair Follicle Bulge with the Cell Surface Marker CD34”, J. Invest. Dermatol. (2003), vol. 120, pp. 501-511.
Weinstein, et al. “Cardiac Peroxynitrite Formation and Left Ventricular Dysfunction following Doxorubicin Treatment in Mice”, J. Pharmacol. Exp. Ther. (2000), vol. 294, No. 1, pp. 396-401.
Winter, et al. “Humanized antibodies”, TIPS (1993), vol. 14, pp. 139-143.
Woolard, et al. “VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant: Mechanism of Action, In vivo Effect On Angiogenesis and Endogenous Protein Expression”, Cancer Research (2004), vol. 64, No. 21, pp. 7822-7835.
Zhang, et al. “Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse”, Blood (2004), vol. 103, No. 2, pp. 617-626.

Affiliated with

Also associated with

Rating

Vascular endothelial growth factors and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial growth factors and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial growth factors and methods of their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4290595